Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation.
about
Mast cells as effectors in atherosclerosisLysophosphatidic Acid Is Associated with Atherosclerotic Plaque Instability by Regulating NF-κB Dependent Matrix Metalloproteinase-9 Expression via LPA2 in Macrophages.Circulating immunoglobulins are not associated with intraplaque mast cell number and other vulnerable plaque characteristics in patients with carotid artery stenosis.Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis.LC-MS based metabolomics identification of novel biomarkers of tobacco smoke-induced chronic bronchitis.Modulation of Hexadecyl-LPA-Mediated Activation of Mast Cells and Microglia by a Chemical Probe for LPA5.Lysophospholipids in coronary artery and chronic ischemic heart disease.Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acidThe autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation.Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis.Liver-specific deletion of the Plpp3 gene alters plasma lipid composition and worsens atherosclerosis in apoE-/- mice.Mast cells in human and experimental cardiometabolic diseases.Molecular histology of arteries: mass spectrometry imaging as a novel ex vivo tool to investigate atherosclerosis.CD14 is a key mediator of both lysophosphatidic acid and lipopolysaccharide induction of foam cell formation.Lysophosphatidic acid and cardiovascular disease: seeing is believing.Inhibition of lysophosphatidic acid receptors 1 and 3 attenuates atherosclerosis development in LDL-receptor deficient miceComplement factor C5a induces atherosclerotic plaque disruptions.Lysophosphatidic acid receptor mRNA levels in heart and white adipose tissue are associated with obesity in mice and humans.Lysophosphatidic Acid Signaling in Obesity and Insulin Resistance.Targeting Platelet G Protein-Coupled Receptors for Antithrombotic Therapy
P2860
Q26995160-9BDAE76B-CA46-4977-A3A4-AECD0E311F07Q33607215-E90A0A0B-D9BF-417D-A347-930189C3FE56Q35106514-4EF80A67-09FD-4ABE-AF3E-A7740A3D6224Q35217048-0F82F9A0-C82C-4237-8F57-F1BF768AB646Q35781857-C3254FA7-C545-44FD-B6E5-CB410025B575Q35904954-B5027FC8-4FC5-456A-AF7D-0098000358A5Q36198168-C3AEDB97-79DE-4594-B467-BBA2962AE551Q37305392-98BAC021-637A-46E6-8890-DB327649F43CQ37527792-847FC2C6-A5E0-4B36-AD57-3C7D81B8648DQ37620329-33CCA877-DA0E-45C7-956E-22DB936D9DBFQ37698833-49A6168A-AE4A-4568-A85A-317A17CB6A26Q38563903-3377F68C-25B5-47F0-A14A-E17D2B0309ECQ38630695-911542E0-6B35-4655-A921-A1A3DE068E47Q38680111-BB565D50-C458-4116-9162-35A66CF6B233Q39741379-EDA05B1D-AF46-465E-BF09-D9A472985590Q42363985-68E7D06A-5BDF-4F44-A262-54D51589DA1EQ43033776-6E609EDB-EB88-4C13-92CC-E7DDD4AB25EFQ47220587-17EB996D-2892-4057-B555-24833E827746Q52640499-EC5F0349-A450-47FF-929B-F95E22B3F2A1Q58291538-ADA87563-E64E-4851-98FF-13525C3BECE4
P2860
Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Lysophosphatidic acid triggers ...... reasing vascular inflammation.
@en
Lysophosphatidic acid triggers ...... reasing vascular inflammation.
@nl
type
label
Lysophosphatidic acid triggers ...... reasing vascular inflammation.
@en
Lysophosphatidic acid triggers ...... reasing vascular inflammation.
@nl
prefLabel
Lysophosphatidic acid triggers ...... reasing vascular inflammation.
@en
Lysophosphatidic acid triggers ...... reasing vascular inflammation.
@nl
P2093
P2860
P50
P921
P356
P1476
Lysophosphatidic acid triggers ...... creasing vascular inflammation
@en
P2093
Erik A L Biessen
H Maxime Lagraauw
Johan Kuiper
Martine Bot
Theo J C van Berkel
P2860
P304
P356
10.1194/JLR.M032862
P577
2013-02-10T00:00:00Z